Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Remus Pharmaceuticals Ltd (REMUS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: REMUS Trading | Small Cap | Remus Pharmaceutical Share Price
BSE Share Price
Not Listed
Not Listed
Remus Pharmaceuticals Ltd (REMUS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: REMUS Trading | Small Cap | Remus Pharmaceutical Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹1,043 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹31.4
TTM Sales
₹854 Cr.
Book Value per Share
₹297.9
P/E Ratio
28.19
Lower than its 5-year historical median
Industry PE
38.9
Price to Book (P/B)
2.97
Lower than its 5-year historical median
Price to Sales (P/S)
1.22
Lower than its 5-year historical median
EV/EBITDA
16.65
Lower than its 5-year historical median
Dividend Yield
INF%
Profitability Efficiency
Return on Equity (ROE)
18.58%
Outperforms industry median
Return on Capital Employed (ROCE)
21.89%
Outperforms industry median
Return on Assets (ROA)
10.03%
Operating Profit Margin
7.4%
Net Profit Margin
6.19%
Gross Profit Margin
7.9%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
23.8%
Operating Profit Growth (1 Year)
-
57.77%
Net Profit Growth (1 Year)
-
58.24%
Asset Quality
Promoter Holding
70.95%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹339 Cr.
Equity
₹11.8 Cr.
Face Value
₹10
All Time Low / High
₹0.00 / 0.00
Check Before You Invest
Quality
Not GoodValuation
Somewhat UndervaluedCheck Valuation charts
Price Trend
Strong
Is Remus Pharmaceuticals Ltd a good quality company?
Remus Pharmaceuticals Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Remus Pharmaceuticals Ltd performance compare with that of its Peers?
Revenue growth of Remus Pharmaceuticals Ltd vs industry peers?
Remus Pharmaceuticals Ltd revenue CAGR is %, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Remus Pharmaceuticals Ltd?
Promoters hold 70.95% of the Remus Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Remus Pharmaceuticals Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of -41.32% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Remus Pharmaceuticals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 47.8% | 48.8% | 93.1% | 68.8% | 24.9% | 13.5% | - |
| Value Creation Index ⓘ | 2.4 | 2.5 | 5.7 | 3.9 | 0.8 | 0.0 | - |
Growth Parameters ⓘ |
|||||||
| Sales ⓘ | 11.9 | 18.4 | 24.7 | 45 | 63.9 | 79.2 | 94 |
| Sales YoY Gr. | - | 54.5% | 34.1% | 82.3% | 42% | 23.8% | - |
| Adj EPS ⓘ | 0.8 | 1.1 | 4.1 | 9.3 | 13.8 | 16.4 | 21 |
| YoY Gr. | - | 35.7% | 259.7% | 126.6% | 48.2% | 18.7% | - |
| BVPS (₹) ⓘ | 2.5 | 3.8 | 8.2 | 22.1 | 130.6 | 205.6 | 276.4 |
| Adj Net Profit ⓘ | 0.7 | 0.9 | 3.3 | 8.1 | 16.2 | 19.3 | 25 |
| Cash Flow from Ops. ⓘ | 1.3 | 2.8 | 5 | 5.3 | 6.3 | 15.6 | - |
| Debt/CF from Ops. ⓘ | 0.3 | 0.1 | 0 | 1.5 | 0.2 | 0.1 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 46% | 47.4% | 23.8% | ||||
| Adj EPS ⓘ | NA | 81.1% | 58.6% | 18.7% | ||||
| BVPSⓘ | NA | 141% | 192.5% | 57.5% | ||||
| Share Price | - | - | -41.3% | 8% | ||||
Key Financial Parameters ⓘ
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 33.2 | 36 | 68.1 | 62.7 | 18.8 | 9.7 | 8.7 |
| Op. Profit Mgn % ⓘ | 3.3 | 4.1 | 16.7 | 23.4 | 32.8 | 32.8 | NAN |
| Net Profit Mgn % ⓘ | 5.6 | 5 | 13.3 | 17.9 | 25.4 | 24.3 | 26.3 |
| Debt to Equity ⓘ | 0.2 | 0.1 | 0 | 0.4 | 0 | 0 | - |
| Working Cap Days ⓘ | 0 | 132 | 155 | 79 | 140 | 232 | 0 |
| Cash Conv. Cycle ⓘ | 0 | -7 | -33 | -14 | 7 | 30 | 0 |
Valuation of Remus Pharmaceutical - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'24 | Mar'25 |
|---|---|---|
| Sales | 213 | 620 |
| Operating Expenses ⓘ + | 184 | 575 |
| Operating Profit ⓘ | 29 | 46 |
| Operating Profit Margin (%) | 13.6% | 7.4% |
| Other Income ⓘ + | 3 | 5 |
| Interest ⓘ | 1 | 1 |
| Depreciation ⓘ | 1 | 2 |
| Profit Before Tax ⓘ | 30 | 47 |
| Tax ⓘ | 6 | 9 |
| Profit After Tax | 24 | 38 |
| PAT Margin (%) | 11.4% | 6.2% |
| Adjusted EPS (₹) | 17.5 | 24.7 |
| Dividend Payout Ratio (%) | 4.30% | 3% |
| PARTICULARS | Mar'24 | Mar'25 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 158 | 256 | |||||||||
| Debt + | 11 | 20 | |||||||||
| Minority Interest | 18 | 27 | |||||||||
| Trade Payables | 94 | 71 | |||||||||
| Others Liabilities ⓘ | 53 | 58 | |||||||||
| Total Liabilities ⓘ | 333 | 433 | |||||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 14 | 16 | |||||||||
| CWIP ⓘ | 0 | 0 | |||||||||
| Investments ⓘ | 105 | 186 | |||||||||
| Inventories | 43 | 52 | |||||||||
| Trade Receivables | 115 | 108 | |||||||||
| Cash Equivalents | 14 | 8 | |||||||||
| Others Assets ⓘ | 43 | 63 | |||||||||
| Total Assets ⓘ | 333 | 433 | |||||||||
| PARTICULARS | Mar'24 | Mar'25 |
|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 1 | 7 |
| Cash Flow From Investing Activity ⓘ + | -30 | -11 |
| Cash Flow From Financing Activity ⓘ + | 28 | 6 |
| Net Cash Flow ⓘ | -1 | 3 |
| PARTICULARS | Mar'24 | Mar'25 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 15.4 | 18.58 | ||||||||
| ROCE (%) | 18.12 | 21.89 | ||||||||
| Asset Turnover Ratio | 0.64 | 1.62 | ||||||||
| PAT to CFO Conversion(x) | 0.04 | 0.18 | ||||||||
| Working Capital Days | ||||||||||
| Receivable Days | 197.60 | 65.70 | ||||||||
| Inventory Days | 73.90 | 27.90 | ||||||||
| Payable Days | 209.40 | 56.50 | ||||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Remus Pharmaceuticals Ltd FAQs
The current trading price of Remus Pharmaceutical on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Remus Pharmaceutical stood at ₹1,042.7 Cr
The latest P/E ratio of Remus Pharmaceutical as of 31-Dec-1969 is 42.20.
The latest P/B ratio of Remus Pharmaceutical as of 31-Dec-1969 is 3.20.
The 52-week high of Remus Pharmaceutical is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Remus Pharmaceutical is ₹93.99 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Remus Pharmaceuticals Ltd is a below average quality company.
The key valuation ratios of Remus Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Remus Pharmaceuticals Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Remus Pharmaceuticals Ltd
The company was originally incorporated as ‘Remus Pharmaceuticals Private Limited’ as a private limited company, under the provisions of the Companies Act, 2013 vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat. Later on, pursuant to a special resolution passed by its shareholders in the Extra-Ordinary General Meeting held on January 02, 2023, the company was converted from a private limited company to public limited company and consequently, the name of the company was changed to ‘Remus Pharmaceuticals Limited’, and a fresh certificate of incorporation dated January 06, 2023 was issued to the company by the Registrar of Companies, Ahmedabad.
The company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries. Having cultivated strong and dependable customer relationships ranging from Generic distributors, regional distributors and Multinational distributors to Hospitals and Clinics through a responsive distribution network, its clients are spread in various countries. It looks forward to form long lasting relationships that enhance the lives of its patients.
The company is majorly engrossed in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical finished formulations and products. Depending upon business requirements, it gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing. Such manufacturing is on principle to principle basis. It has its presence through registered and/or under registration products in countries namely Bhutan, Bolivia, Chile, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Jamaica, Kuwait, Madagascar, Malaysia, Hong Kong, Myanmar, Panama, Trinidad and Tobago, Uzbekistan, Venezuela, Vietnam etc. It deals in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.
Business area of the company
The company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient).
Products of the company
- Cardiovascular
- Anti-DIABETIC
- Central nervous system
- Analgesic / Anti-Inflammatory
- Anti-Allergy
- Anti-Infective / Anti biotics
- Hormonal
- Urology
- Immuno suppressant
- Erectile dysfunction
- Effervescent
- Other formulations
History and milestones
- 2015: The company was incorporated as a private limited company under the name ‘Remus Pharmaceuticals Private Limited’.
- 2023: Conversion of the company from Private Limited to Public Limited Company.
You have 44 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
